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Under normal circumstances, T cells are triggered when the TCR binds to the
MHC antigen complex onanothercell. This activation can also be induced by anti-
bodies (Abs) that bridge the CD3/TCR complexto a structure onanothercell, such
as the Fc receptor on monocytes (1) or, in the case of hybrid Abs, to structures on
target cells (2, 3).
Anti-CD3 mAbs, being bivalent, can also crosslink CD3 molecules on the same
T cell and, in this way, deliver a signal. Although this signal usually does not lead
to the full display ofT cell effector potential, the triggering effect ofbivalent anti-
CD3 Abs can bemeasured by assessinga rise in the intracellular Cat+ or by adown-
regulation ofthe CD3/TCR complex itself (4, 5).
In the present study we asked whether the monovalent binding ofa ligand to the
CD3/TCR complex would be able to transduce a triggering signal to the Tcells.
As a stable monovalent ligand we used a hybrid mAb in which one binding site
isdirected tothe CD3 andthe otherto a tumor-associated antigenpresent on ovarian
carcinoma (OVCA) cells. In the absence ofOVCA cells this Ab will bind monova-
lently toCD3, but will not be able to either crosslinkor bridge the CD3/TCR com-
plex. Here we show that in the absence oftumor cells this Ab does not transduce
triggering signals to theT cells as measured byvarious criteria. This property makes
thisAb a suitable reagentto arm invitroCTLthat subsequently retain theirspecific
effector function for extended periods of time.
Antibodies.
￿
mAbs were purified over protein A-Sepharose (Pharmacia Fine Chemicals,
Uppsala, Sweden)from supernatants ofhybridomas that havebeendescribedbefore (6). The
Igproducedby thehybrid hybridomaMOV 18TR66was dialyzed against an acetatebuffer
(25 mM; pH 5.6) and fractionated on a Mono S column (HR 5/5; Pharmacia Fine Chem-
icals) by elution with a linear salt gradient (0-100 mM NaCI).
TCells.
￿
Resting peripheral blood T cellswere purified from huffycoats and further frac-
tionated on Percoll gradients(Pharmacia FineChemicals)asdescribed (7). The highdensity
T cell fraction was furtherdepleted ofnonT cells by treatment with a cocktail ofmAbs and
rabbit complement (7). The cells were >99% CD2', >95% CD3', and negative for class II
andLeu-M3 markers. Alloreactive CTLclones wereisolated andmaintained asdescribed(6).
T Cell Proliferation.
￿
105 T cells were cultured in the presence or absence of 3 x 104 ir-
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radiated (6,000 rad) ovarian carcinoma cells (OVCA 432; provided by Dr. R. Knapp, Dana
Farber Cancer Institute, Boston, MA) or 3 x 104 irradiated peripheral blood monocytes in
200 j1 of Iscove's modified Dulbeccds medium supplemented with 5% FCS in 96-well flat-
bottomed microplates. Proliferation was measured after 72 h by pulsing with [3H]thymidine
(Amersham International, Amersham, UK; 9.25 kBq/well; 185 MBq/mmol sp act).
Determination of Caz' Mobilization.
￿
T cells were loaded with Indo-1-AM (Calbiochem-
Behring Corp., La Jolla, CA) as previously described (8), incubated on ice with saturating
concentrations ofmonovalent or bivalent anti-CD3 Abs, and washed with ice-cold PBS. The
cells were resuspended into PBS (2 mM Ca2' at 37°C) and changes in Indo-1 fluorescence,
as a measure of the cytosolic Cat' concentration, were recorded with a FACS 440 as de-
scribed (8). This protocol of prebinding the anti-CD3 Ab was chosen because it minimizes
the effect of differences in Ab avidities. In some experiments a rabbit anti-mouse antiserum
(Dakopatts, Glostrup, Denmark) was added to the PBS to crosslink the prebound anti-CD3 Ab.
Retargeting Cytotoxic T Cells.
￿
5 x 103 "Cr-labeled target cells were incubated with effector
cells at different E/T ratios in the presence or absence of various mAbs. Specific "Cr re-
lease was measured after4 h. In some experiments the CTL were pulsed with different con-
centrations ofhybrid anti-CD3/anti-OVCA Ab on ice, washed, recultured at 37°C, and tested
at different times for their capacity to kill OVCA cells.
Results
Purification and Characterization ofa Bispecfic Anti-CD3/anti-OVCA Ab.
￿
The Abs pro-
duced by the hybrid hybridoma MOV18TR66 (a fusion product of an IgG1 anti-
CD3 and an IgG1 anti-OVCA hybridoma; reference 6) were purified over protein
A-Sepharose and fractionated on a Mono S column. Fig. 1 shows that the separa-
tion procedure yields three distinct protein peaks that represent the three possible
H chain combinations (9).
The hybrid anti-CD3/anti-OVCA Ab can be detected at the level of 1 ng/ml by
its capacity to retarget CTL against the tumor cells. This activity was detected only
at the beginning of the middle peak (fractions 25-32).
The bivalent anti-CD3 Ab can be detected by its capacity to bridge a CTL to
other CD3+ cells, resulting in the reciprocal killing of the T cells (6). This activity
was present in the third protein peak and was absent in fractions <34, indicating
that the bispecific anti-CD3/anti-OVCA Ab was separated from the bivalent anti-CD3.
Binding of a Monovalent Anti-CD3/Anti-OVCA Ab to T Cells Does not Induce Increase
in Cytosolic Ca" or IL-2 Responsiveness. We tested whether the anti-CD3/anti-OVCA
Ab was able to trigger T cells in the absence of OVCA cells. As an early triggering
event we measured intracellular Cat+ mobilization, an event that can be detected
S
a
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FIGURE 1.
￿
Separation ofthe hybrid anti-CD3/
anti-OVCA from the bivalent anti-CD3. Pro-
tein A-purified Igs produced by the hybrid hy-
bridoma were separated on a Mono S column.
A280 (
￿
); percent ofcytotoxicity on OVCA
432 cells obtained by retargeting a nonspecific
CTL clonewith a 1 :2,500 dilution ofeach frac-
tion (0); reciprocal killing ofthe CTL in the pres-
ence of a 1 :100 dilution of the fraction (O).ROOSNEK AND LANZAVECCHIA
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FIGURE 2. Monovalent anti-CD3 does not induce
Cat* mobilization in T cells. T cells were incubated at
0°C with saturating amounts ofeither bivalent anti-CD3
Ab (TR 66) orwith anti-CD3/anti-OVCA Ab (fraction
no. 28 of the ion exchange purification), washed, and
resuspended in PBS, 2 mM Ca2* at 37°C in the absence
or in the presence ofa second crosslinking rabbit anti-
mouse Ab. Cells were analyzed directly using a FACS.
Histograms show the Indo-1 violet/blue ratio, propor-
tional to the cytosolic Cat* concentration. Dotted line,
cells without Ab.
within minutes after receptor perturbation. Fig. 2 shows that when T cells are in-
cubated with saturating amounts of either bivalent anti-CD3 or monovalent anti-
CD3/anti-OVCA Ab, only the bivalent anti-CD3 is able to induce Cat+ mobiliza-
tion, while the monovalent Ab is not effective at all, in spite of the fact that more
(1.5 times) Ab has bound to the cells (see below). Moreover, both Abs are equally
effective at inducing Cat+ mobilization when crosslinked by a second rabbit
anti-mouse Ab, indicating that the inability of the hybrid Ab to trigger is only due
to its monovalency.
We next tested whether the monovalent anti-CD3 could induce IL-2 responsive-
ness in resting T cells. Table I shows that, while the bivalent anti-CD3 can induce
proliferation in thepresence ofexogenous IL-2, the monovalent anti-CD3 is ineffec-
tive. In contrast, proliferation did occur after addition of OVCA cells or monocytes,
i.e., in conditions that lead to the bridging of the CD3/TCR complex to another
cell via the Fc receptor or via the OVCA-specific antigen.
Monovalent Anti-CD3 Does not Induce Downregulation ofthe CD3 Complex.
￿
Bivalent
anti-CD3 Abs are known to downregulate the CD3/TCR complex, resulting in the
inhibition of T cell function (5). We asked whether the ligation of the CD3 by a
monovalent ligand would have a similar effect. T cells were incubated with bivalent
or monovalent anti-CD3 Abs at saturating concentrations at 37°C and theAb present
on the cell surfacewasdetected at different times by staining with a goat anti-mouse
TABLE I
Hybrid Anti- CD3/Anti-0VCA Abs Activate T Cells when
Bridged to other Cells, but Fail to Induce IL-2
Responsiveness when Bound Monovalently
[3H]Thymidine incorporated in the presence of:
PBT were cultured with anti-CD3 Abs (20 ng/ml) or with anti-CD3/anti-OVCA
(500 ng/ml) in the presence of accessory cells or 100 U/ml IL-2 . Thymidine in-
corporation was measured after 72 h. Comparable results were obtained in ex-
periments using concentrations of hybrid Ab ranging from 50 ng/ml to 2 !2g/ml.
TR88 TRBS * Raht
028 ate+wwl
Cells in culture Medium Anti-CD3 Anti-CD3/anti-OVCA
cpm
PBT 50 50 NT
PBT + MO 50 21,450 28,500
PBT + OVCA432 600 900 6,750
PBT + IL-2 2,100 10,600 1,800300
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FITC. Table II, Exp. 1, shows that incubation with the bivalent anti-CD3 induced
a >90% downregulation ofCD3 in 24 h, while the monovalent anti-CD3/anti-OVCA
Ab, although binding at 1.5 times the level, did not induce any downregulation of
CD3. Similarresultswere obtained when the Tcells were incubated with the hybrid
Ab, washed, and recultured at 37°C (Table II, Exp. 2). In this case, the Ab on the
cell surface decreased with time, but the total number of CD3 molecules, detected
by restaining with anti-CD3, remained unaffected.
Monovalent Anti-CD3/Anti-OFCA Abs Can Be Used to Arm T Cells that Retain Antitumor
Activityfor Prolonged Periods of Time. The previous results show that purified hybrid
Abs in the absence of OVCA cells fail to trigger T cells or induce downregulation
of the CD3/TCR complex. These data suggest that this Ab mightbe avery suitable
reagent to confer antitumoractivity to Tcells that would then maintain this activity
until theencounterwith thetarget cell. To exploit this property we incubated aCTL
clone with different subsaturating concentrations of anti-CD3/anti-OVCA Ab, then
washed and recultured the cells at 37°C, andtested these "armed" cells afterdifferent
periods of time fortheir capacity to kill OVCA cells. Fig. 3 shows that armed CTLs
efficiently kill OVCA cells, even when a small number of receptors are occupied
by the Ab (see for comparison the data in Table II). Near plateau values of killing
were obtained with only 317o of receptors occupied and substantial killing was still
observed when the number of receptors occupied was toolow to detect by immuno-
fluorescence. Furthermore, in spite of the loss of Ab from the membrane, the CTL
retained theirspecific lyticcapacity forprolongedperiods, andeven 2 dafterpulsing,
cells armed with 100 ng/ml of monovalent Ab still exerted maximal lytic capacity
towards the tumor cell, while no CTL activity against other targets, such as EBV
transformed B cells or T cell blasts, was displayed (data not shown).
TABLE II
Monovatent Anti-CD3 Fails to Induce Downregulation of the CD3 Complex
Exp.
2
T cells (clone AK15) were incubated with Ab at 0°C for 30 min in culture
medium. After this, cells were either directly put at 37°C and cultured in the
presence of Ab (Exp. 1) or washed three times and cultured in the absence
of free Ab (Exp. 2). At the times indicated, the cells were washed and stained
with a goat anti-mouse FITC Ab. Table values are linear fluorescence values,
normalized to 100 for cells stained with bivalent anti-CD3 . The values in paren-
theses are a measure of the total surface CD3, determined by reincubation
of the cells with saturating concentrations of bivalent anti-CD3 followed by
staining with goat anti-mouse FITC Ab.
Time of incubation at 37°C .
Antibody
Linear fluorescence values at:
0 h' 24 h"
Anti-CD3
5 kg/ml 100 8 (7)
Anti-CD3/anti-OVCA
10 wg/ml 147 143 (ND)
Anti-CD3/anti-OVCA
500 ng/ml 57 4 (107)
100 ng/ml 19 2 (98)
10 ng/ml 3 0.7 (103)
1 ng/ml 0.3 0.5 (104)ROOSNEK AND LANZAVECCHIA
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FIGURE 3 . CTL armed with
hybrid Abs maintain the ca-
pacity to kill tumor cells for ex-
tended periods of time. CTL
clone AK15 (CD8' anti-HLA
Cw3) was pulsed with 500
ng/ml (" ), 100 ng/ml (O), 10
ng/ml (A), and 1 ng/ml (A) of
hybrid Ab, washed, and recul-
tured at 37°C. At different
times the cells were tested for
their capacity to kill OVCA 432
targets.
Discussion
Our results demonstrate that the monovalent ligation of the CD3 complex does
not lead to measurable triggering signals in T cells. Using a purified hybrid anti-
CD3/anti-OVCA Ab, we show that the binding ofthis monovalent ligand to T cells
does not lead to: (a) Cat+ mobilization; (b) IL-2 responsiveness; and (c) downregu-
lation oftheCD3/TCR complex. The lack of stimulatory capacity ofthis Ab is due
to its monovalency, since the same Ab is capable of triggering Cat+ mobilization
when crosslinked by a second Ab and, when bridged to OVCA cells, it stimulates
proliferation and cytotoxicity. These data, therefore, indicate that crosslinking or
bridging are required for signal transduction in T cells.
Our results differ from those of Oettgen et al . (4), who reported that anti-CD3
Fab' fragments prepared from OKT3 can trigger Cat+ mobilization in a T cell
tumor line. We do not have a simple explanation for this discrepancy. One possi-
bility is that the tumor T cells might have a special behavior or that the Abs used
in that study have a different effect because they recognize a different epitope.
We have exploited the lack of triggering capacity of this hybrid Ab to arm CTL
in vitro for specific killing. This strategy, originally suggested by Perez et al. (10)
and by Staerz and Bevan (11), requires that theAb used for arming should not lead
to activation and reciprocal killing of the CTL or to downregulation of the TCR.
We show here that the use of a monovalent anti-CD3 Ab meets both criteria. First,
reciprocal T cell killing (6) canbe avoidedby removing thebivalent anti-CD3 . Killing
of FcR+ targets can be avoided by the use of F(ab)2 fragments (6), which are equally
effective in retargeting a CTL. Second, specific CTL capacity is retained until the
encounter with the target cell, because monovalent anti-CD3 does not lead to cap-
ping (12) or downregulation of the CD3/TCR complex.
It is remarkable that a CTL can be armed for killing of OVCA cells by pulsing
with a subsaturating concentration of hybrid Ab. Apparently, specific recognition
can occur when the fraction of CD3 molecules with hybrid Ab bound is at least 10
times lowerthan the minimumlevel of molecules detectable by immunofluorescence,
i.e., with a margin of error of the order of 100 molecules per cell.302
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Summary
We used a purified bispecific antibody (Ab) against CD3 and an ovarian carci-
noma (OVCA) antigen to ask whether the binding ofa monovalent ligand to CD3
can induce triggering ofT cells. In the presence of OVCA cells, this Ab bridges
the CD3 complex to the target cell and triggers proliferation and cytotoxicity in T
cells. In the absence oftarget cells, however, this monovalent Ab, even when bound
to T cells at high levels, fails to induce any increase in cytosolic Cat+, nor does it
induce responsiveness to IL-2 or modulation of the CD3 complex.
Because it is inert when bound monovalently, this hybrid Ab can be used to arm
in vitro CTL clones, which then retain the capacity to kill the specific tumor for
up to 2 d.
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